An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

XTANDI®

Drug Information Related Patent

Hold Company

ASTELLAS

Learn More

Dosage and Administration

CAPSULE;ORAL

Specification

40MG

Indication

XTANDI® treats castration-resistant prostate cancer (CSPC) and metastatic castration-sensitive prostate cancer (mCSPC).

Use

Instructions for Use

API

ENZALUTAMIDE

API Structure

We Supply

ENZALUTAMIDE

Note:

In-house Standard
Facility GMP
USMF/CDE/ASMF/DMF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
7709517	2027/8/13
8183274	2026/8/24
9126941	2026/5/15

API Patent

Patent No	Expiration Date
9126941	2026/5/15

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION